Company Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
803.17 ^USD	+2.49%		+2.25%	+4.06%

13/02	HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating	MT
12/02	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,585,058, According to a Recent SEC Filing	MT

Business description: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:

- revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%);

- revenues from product sales (30%);

- revenues from sales of technology licenses and subcontracted research services (4.9%).

At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.

Number of employees: 15,410

Sales by Activity: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Discovery, Development, and Commercialization of Medicines for Serious Diseases	1.61TCr	1.22TCr	1.31TCr	1.42TCr	1.43TCr

See all business segments

Geographical breakdown of sales: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Regeneron Pharmaceuticals, Inc.

Manager	Title	Age	Since
George Yancopoulos PSD	President	66	01/01/2001
Leonard Schleifer CEO	Chief Executive Officer	73	08/01/1988
Christopher Fenimore DFI	Director of Finance/CFO	55	05/02/2024
Andrew Murphy CTO	Chief Tech/Sci/R&D Officer	68	01/01/2019
Melissa Lozner CMP	Compliance Officer	-	01/01/2022

See REGENERON PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.

Director	Title	Age	Since
Leonard Schleifer CHM	Chairman	73	09/06/2023
Michael Brown BRD	Director/Board Member	85	01/06/1991
Joseph Goldstein BRD	Director/Board Member	85	01/06/1991
George Sing BRD	Director/Board Member	76	08/01/1988
George Yancopoulos CHM	Chairman	66	09/06/2023
Arthur Ryan BRD	Director/Board Member	83	01/01/2003
Christine Poon BRD	Director/Board Member	73	12/11/2010
Bonnie Bassler BRD	Director/Board Member	63	12/09/2016
Huda Zoghbi BRD	Director/Board Member	71	12/09/2016
N. Coles BRD	Director/Board Member	65	17/02/2017

Composition of the Board of Directors

Shareholders: Regeneron Pharmaceuticals, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 8.787 %	90,75,153	8.787 %	6 729 M $
BlackRock Advisors LLC 6.241 %	64,46,180	6.241 %	4 780 M $
STATE STREET CORPORATION 4.542 %	46,91,223	4.542 %	3 478 M $
Dodge & Cox 4.406 %	45,50,845	4.406 %	3 374 M $
JPMorgan Investment Management, Inc. 3.816 %	39,41,443	3.816 %	2 922 M $

Name	Equities	%	Valuation
Leonard Schleifer 82.56 %	17,25,565	82.56 %	1 279 M $
George Yancopoulos 2.045 %	42,750	2.045 %	32 M $
Fineco Asset Management DAC 1.295 %	27,060	1.295 %	20 M $
BG Fund Management Luxembourg SA 0.2782 %	5,815	0.2782 %	4 M $
Ersel Asset Management SGR SpA 0.162 %	3,386	0.162 %	3 M $

List of REGENERON PHARMACEUTICALS, INC. shareholders

Holdings: Regeneron Pharmaceuticals, Inc.

Name	Equities	%	Valuation
INTELLIA THERAPEUTICS, INC. 3.2%	37,02,995	3.2%	49 M $
ADICET BIO, INC. 0.63%	60,511	0.63%	483 483 $

Company details: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

10591-6707, Tarrytown

+914 847 7000

http://www.regeneron.com

address Regeneron Pharmaceuticals, Inc.(REGN)

Group companies: Regeneron Pharmaceuticals, Inc.

Name	Category and Sector
Regeneron Ireland DAC Regeneron Ireland DAC Operates as a biotechnology company which develops medicines for serious diseases
Regeneron Ireland DAC Regeneron Ireland DAC Operates as a biotechnology company which develops medicines for serious diseases

See all subsidiaries

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+2.49%	+2.25%	+19.12%	+5.13%	8.24TCr
UCB	+2.12%	+6.68%	+49.35%	+256.78%	6.3TCr
SAMSUNG BIOLOGICS CO.,LTD.	-0.52%	+71.00%	+71.00%	+71.00%	5.49TCr
CSL LIMITED	-1.43%	-16.89%	-40.94%	-50.82%	5.11TCr
BIOGEN INC.	+0.52%	-2.32%	+41.94%	-32.34%	2.88TCr
INCYTE CORPORATION	+0.35%	-6.73%	+44.41%	+26.25%	2.01TCr
INNOVENT BIOLOGICS, INC.	-0.51%	+11.45%	+147.14%	+105.09%	1.97TCr
SWEDISH ORPHAN BIOVITRUM AB	-0.73%	+2.98%	+25.96%	+66.71%	1.58TCr
MODERNA, INC.	+5.29%	+2.97%	+32.30%	-75.37%	1.65TCr
BRIDGEBIO PHARMA, INC.	-1.06%	+10.58%	+138.43%	+549.27%	1.45TCr
Average	+0.65%	+1.19%	+52.87%	+92.17%	3.67TCr
Weighted average by Cap.	+0.84%	+0.18%	+39.35%	+74.53%